U.S. states’ tax revenues from legal cannabis sales have surpassed $20 billion in total since the recreational marijuana ...

Teva Pharmaceutical Industries reported a smaller than expected rise in first-quarter profit citing higher impairments of ...

Court records shed light on a lucrative two-man drug economy featuring an oddball pairing of a government contractor and a ...

With U.S. officials considering loosening restrictions on marijuana companies, Colorado cannabis companies are looking ...

Cencora beat Wall Street estimates for second-quarter profit on Wednesday, driven by robust demand for costly specialty medicines that treat complex diseases such as cancer and rheumatoid arthritis.

NRXP has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine ... NRXP forecasts first commercial revenue in 2024 from sales of ketamine and related technologies. Company ...

Supply continues to be tight, however, and the company anticipates further sales growth to be limited by how quickly it can bring on additional production capacity.

The Hyderabad-based drug major had reported a profit after tax of Rs 959 crore in the January-March quarter of 2022-23 fiscal.

Shares of cannabis companies surged on Tuesday afternoon after the U.S. Department of Justice (DoJ) moved to reclassify ...

A recent study shows that net government revenue from alcohol sales was $13 billion in 2020 while the net social costs from ...

Dr Reddy's Laboratories announced a 36% rise in its consolidated profit after tax (PAT), reaching Rs 1,307 crore for the March 2024 quarter.

Dr Reddy's Laboratories on Tuesday reported a 36 per cent increase in its consolidated profit after tax at Rs 1,307 crore for the quarter ended March 2024, aided by robust sales in the US market.